Brian S. Kim is the Sol and Clara Kest Professor, Vice Chair of Research, and Site Chair of Mount Sinai West and Morningside in the Kimberly and Eric J. Waldman Department of Dermatology at Icahn School of Medicine at Mount Sinai.
He was a Howard Hughes Medical Institute-National Institutes of Health Research Scholar under Stephen I. Katz, and completed his residency in dermatology at the Perelman School of Medicine at the University of Pennsylvania.
[9] Kim's group also was the first lab to identify JAK1 signaling in sensory neurons,[10] building on previous research which showed a significant reduction of itch symptoms in response to treatment with JAK inhibitors.
[11][12] While these previous works investigated JAK inhibition as an anti-inflammatory treatment, Kim and colleagues found that disruption of neuronal JAK1 signaling limits both inflammatory and non-inflammatory itch, suggesting that JAK inhibitors may represent a novel neuromodulatory approach to target itch in atopic dermatitis[13] Kim also designed the pivotal phase 2 clinical trial that ultimately led to the approval of topical ruxolitinib for atopic dermatitis.
The text and its release have been received by the Wikimedia Volunteer Response Team; for more information, see the talk page.